Half-year report · Q2
4005.TEDINET S100UN1U
Period2024-04-01 → 2024-09-30
Filed2024-11-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.24T | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥2.45T | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.19T | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥121.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥133.7bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥30.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥462.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥103.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥6.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥311.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥76.3bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥20.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | −¥465.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥107.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥3.72T | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥3.93T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥4.38T | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥2.63T | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥2.77T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.09T | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.16T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.55T | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.49T | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥909.8bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥965.8bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.22T | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥273.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥217.4bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥277.7bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥305.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥63.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥51.3bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥115.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥74.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥112.2bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥79.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥75.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥49.2bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥140.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-3.99 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-190.69 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-46.69 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| Equity ratio | 24.5% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.5% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 27.9% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥78.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥41.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥37.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥15.7bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥50.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥50.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥10.0bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥147.5bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥138.8bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥8.7bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥8.7bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥405.9bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥403.0bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.9bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥36.6bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥239.5bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥238.4bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥13.6bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥224.6bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥224.3bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥235m |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥37.5bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥195.2bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥195.2bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1m |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥470m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.21T |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.20T |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥13.0bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥23.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥76.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥34.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥41.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥4.3bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥56.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥56.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥7.9bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥159.8bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥149.9bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9.9bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.5bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥393.1bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥390.3bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥44.4bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥243.1bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥241.2bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥7.6bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥203.9bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥203.7bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥220m |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥17.8bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥166.9bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥166.9bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1m |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥65.5bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.17T |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.15T |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥14.7bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | −¥93.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 919
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from issuance of bonds fin cf IFRS | Prior1YTDDuration | 39836000000 | JPY |
| Proceeds from issuance of bonds fin cf IFRS | CurrentYTDDuration | 99161000000 | JPY |
| Redemption of bonds fin cf IFRS | Prior1YTDDuration | -10000000000 | JPY |
| Redemption of bonds fin cf IFRS | CurrentYTDDuration | -20000000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YTDDuration | -8991000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -8972000000 | JPY |
| Dividends paid fin cf IFRS | Prior1YTDDuration | -9847000000 | JPY |
| Dividends paid fin cf IFRS | CurrentYTDDuration | -4934000000 | JPY |
| Dividends paid to non controlling interests fin cf IFRS | Prior1YTDDuration | -4283000000 | JPY |
| Dividends paid to non controlling interests fin cf IFRS | CurrentYTDDuration | -2798000000 | JPY |
| Other fin cf IFRS | Prior1YTDDuration | -915000000 | JPY |
| Other fin cf IFRS | CurrentYTDDuration | -801000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | 140238000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | -75384000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 25543000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | -7877000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | -29316000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | 54707000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 305844000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 217449000000 | JPY |
| Net increase decrease in cash and cash equivalents resulting from transfer to assets held for sale IFRS | Prior1YTDDuration | 1135000000 | JPY |
| Net increase decrease in cash and cash equivalents resulting from transfer to assets held for sale IFRS | CurrentYTDDuration | 1200000000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 277663000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 273356000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000EssentialChemicalsAndPlasticsReportableSegmentMember | 390301000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000EnergyAndFunctionalMaterialsReportableSegmentMember | 149888000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000InformationElectronicChemistryReportableSegmentMember | 203672000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000HealthAndAgricultureRelatedReportableSegmentMember | 241223000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000MedicalProductsReportableSegmentMember | 166927000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 1152011000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 34864000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration | 1186875000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000EssentialChemicalsAndPlasticsReportableSegmentMember | 2773000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000EnergyAndFunctionalMaterialsReportableSegmentMember | 9892000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000InformationElectronicChemistryReportableSegmentMember | 220000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000HealthAndAgricultureRelatedReportableSegmentMember | 1833000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000MedicalProductsReportableSegmentMember | 1000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_ReportableSegmentsMember | 14719000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 41318000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_ReconcilingItemsMember | -56037000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration | － | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000EssentialChemicalsAndPlasticsReportableSegmentMember | 393074000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000EnergyAndFunctionalMaterialsReportableSegmentMember | 159780000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000InformationElectronicChemistryReportableSegmentMember | 203892000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000HealthAndAgricultureRelatedReportableSegmentMember | 243056000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E00752-000MedicalProductsReportableSegmentMember | 166928000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_ReportableSegmentsMember | 1166730000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 76182000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_ReconcilingItemsMember | -56037000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |